prognostication and initiation of therapy in polycythemia vera: do we have it right?
Published 7 years ago • 5.5K plays • Length 19:02Download video MP4
Download video MP3
Similar videos
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
17:25
molecular prognostication in essential thrombocythemia and polycythemia vera: does it matter?
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
19:03
assessment of novel treatment options for patients with pv
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
19:36
evolution of the assessment of clinical benefit in polycythemia vera
-
31:05
q&a session for polycythemia vera
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
5:08
polycythemia vera - causes, symptoms, diagnosis, treatment, pathology
-
4:04
polycythemia vera: monitoring patients
-
13:49
“masked” polycythemia vera and polycythemia vera “in evolution”
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera
-
4:31
cytoreductive therapy in polycythemia vera
-
3:53
heterogeneity of polycythemia vera
-
7:45
suspecting polycythemia vera: challenges in diagnosis
-
7:25
polycythemia vera: controlling hct and wbc
-
6:15
interferon’s role in treating polycythemia vera
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera